- Entheon Biomedical (ENBI) expands psychedelics genetic test panel & new clinical research platform
- Improved genetic screening platform to strengthen Entheon’s psychedelic-assisted protocols
- Approximately 30 per cent of the population carries the BDNF ‘Met’ genetic variant, which can impair the secretion of BDNF
- These individuals are more likely to have a decreased response to the antidepressant effects of ketamine therapy
- The company is also pleased to announce it has secured private loans in the aggregate amount of $300,000 from arm’s length parties
- Entheon Biomedical Corp. (ENBI) is in the red at 7.41 per cent, trading at C$0.12 at 10:27 am ET
Entheon Biomedical’s (ENBI) expanded psychedelics genetic testing panel is now available for sale in Canada and the United States.
HaluGen’s Psychedelics Genetic Test Kit now includes a key pharmacodynamic biomarker, the brain-derived neurotrophic factor (BDNF) gene.
This gene can affect the secretion of BDNF protein, which is released due to being dosed with ketamine.
BDNF helps with the growth and maintenance of new neurons and synapses necessary for normal mood regulation and neural connectivity.
Testing for the BDNF Val66Met genetic polymorphism can better help individuals understand their response to ketamine.
Approximately 30 per cent of the population carries the BDNF ‘Met’ genetic variant, which can impair the secretion of BDNF.
These individuals are more likely to have a decreased response to the antidepressant effects of ketamine therapy.
HaluGen’s psychedelics genetic test also includes six other relevant pharmacodynamic, pharmacokinetic and mental health risk biomarkers, including the HTR2A gene, which can impact response to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT.
For the 20 per cent of the population that carry a specific gene variant that influences serotonin receptor density and the CYP2B6 gene, which can decrease the metabolism of ketamine, for the 10-20 percent of people that carry a specific ‘poor metabolizer’ gene variant.
In addition, HaluGen has launched a new software platform that seamlessly allows genetic testing to be added to psychedelic clinical trials and studies.
HaluGen’s clinical research platform enables easy subject enrolment, tracking, genetic analysis and reporting for relevant psychedelic biomarkers.
HaluGen’s platform continues to improve upon Entheon’s strong research, and informational foundation for two key divisions focused on the personalization of psychedelic therapy.
Entheon ID™ focused on the identification, analysis, and predictive use of EEG biomarkers and genetics in selecting and managing drug treatment. Entheon IQ™ focused on developing treatment algorithms through the analysis of patient data.
“HaluGen’s testing panel and software platform are invaluable tools to enable genetic testing for psychedelics,” said Timothy Ko, Chief Executive Officer of Entheon.
“We are excited to be pioneers in psychedelic personalized medicine and hope that our platform can help drive valuable insights and outcomes for psychedelic therapy,” concluded Ko.
The company is also pleased to announce it has secured private loans in the aggregate amount of $300,000 from arm’s length parties under the loan agreements.
The Loans carry no interest and are payable in full on Entheon’s next private placement equity or debt financing closing date. It anticipates using the proceeds of the loans to support its working capital requirements.
Upon conversion of the warrants and the securities issuable will be subject to a four-month and one-day hold period and restrictions on transfer under Canadian securities law.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products to treat addiction and substance use disorders.
Entheon Biomedical Corp. (ENBI) is in the red at 7.41 per cent, trading at C$0.12 at 10:27 am ET.
